With HER2 serving to amplify the signal, HER2/HER3 heterodimers potently activate the PI3K-Akt-mTOR signaling pathway that promotes tumor cell survival, therapeutic resistance, and metastatic dissemination [29]. Here, ERBB3 is linked to neoplasm.